Targeting cyclin D1 for high risk myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 964-965

  Mundle, Suneel D ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

Cyclin D1; MDS; Myelodysplastic syndromes; ON 01910.Na

Indexed keywords

CYCLIN D1; ON 01910NA; PROTEIN KINASE B BETA; RIGOSERTIB; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CONTINUOUS INFUSION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; ENZYME PHOSPHORYLATION; HIGH RISK PATIENT; HUMAN; INFECTION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN TARGETING;

CYCLIN D1; FEMALE; GLYCINE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; SULFONES;

EID: 84862527416     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.023     Document Type: Editorial

References (9)

1. Mundle S., Iftikhar A., Shetty V., Dameron S., Wright-Quinones V., Marcus B., et al. Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem 1994, 42(12):1533-1537.
2. Saberwal G., Broderick E., Janssen I., Shetty V., Alvi S., Lisak L., et al. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 2003, 12:443-450.
3. Saberwal G., Lucas S., Janssen I., Deobhakta A., Hu W.Y., Galili N., et al. Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow. Int J Haematol 2004, 80(2):146-154.
4. Sloand E.M., Pfannes L., Chen G., Shah S., Solomou E.E., Barrett J., et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007, 109:2399-2405.
5. Follo M.Y., Mongiorgi S., Bosi C., Cappellini A., Finelli C., Chiarini F., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67(9):4287-4294.
6. Prasad A., Park I.W., Zhang X., Reddy M.V., Boominathan R., Reddy E.P., et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009, 28(12):1518-1528.
7. Chapman C.M., Sun X., Roschewski M., Aue G., Farooqui M., Stennett L., et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012, (March). [Epub ahead of print].
8. Seetharam M., Fan A.C., Tran M., Xu L., Renschler J.P., Felsher D.W., et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 2012, 36(1):98-103.
9. Olnes M.J., Shenoy A., Weinstein B., Pfannes L., Loeliger K., Tucker Z., et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012, 36(8):982-989.